Evolus to Participate in 9th Annual SVB Leerink Global Healthcare Conference
NEWPORT BEACH, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 9th Annual SVB Leerink Global Healthcare Conference in New York, NY.
| Event: | 9th Annual SVB Leerink Global Healthcare Conference | |
| Format: | Presentation & 1x1 Meetings | |
| Date: | Wednesday, February 26, 2020 | |
| Time: | 3:30 – 3:55pm ET | |
| Location: | Lotte New York Palace Hotel, NY |
An audio webcast of Evolus’ presentation will be available on the investor relations section of Evolus’ website at . Replays of the webcasts will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: .
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Tel:
Email:
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel:
Email:
